Lilly's breast cancer drug succeeds in late-stage study
The drug is already approved to treat other certain forms of breast cancer, but not for reducing the chances of cancer recurring
The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. Picture taken February 1, 2018. REUTERS/Vincent Kessler
Eli Lilly and Co said on Tuesday that its breast cancer therapy Verzenio met the main goal of reducing the risk of it returning in the early stages in a late-stage study, sending its shares up 8.5 percent in pre-market trade.
The drug is already approved to treat other certain forms of breast cancer, but not for reducing the chances of cancer recurring.
Despite progress in the treatment of breast cancer, about 30 percent with a common subtype of early breast cancer are at risk of their cancer returning, according to Eli Lilly.
Keep updated, follow The Business Standard's Google news channel
The US drugmaker said it would submit the data from the trial to regulatory authorities before the end of 2020.
